Profil
Homa Yeganegi est Senior Vice President & Head-Medical Affairs chez Turning Point Therapeutics, Inc. Elle a précédemment occupé le poste de vice-présidente des affaires scientifiques et médicales mondiales chez Halozyme Therapeutics, Inc. et de vice-présidente principale des affaires médicales mondiales chez Clovis Oncology, Inc. Elle est titulaire d'un diplôme de premier cycle de l'université de Téhéran et d'un diplôme d'études supérieures de l'université de Western Australia.
Anciens postes connus de Homa Yeganegi
| Sociétés | Poste | Fin |
|---|---|---|
| AGENUS INC. | Directeur Technique/Scientifique/R&D | - |
| TURG POIN | Corporate Officer/Principal | - |
| CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - |
| HALOZYME THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Homa Yeganegi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Agenus, Inc.
Agenus, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of technologies to treat cancers and infectious diseases | Health Technology |
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
The University of Western Australia
The University of Western Australia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Tehran
University of Tehran Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
















